Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.

about

Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.

Item

http://www.wikidata.org/entity/Q52671185

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Mechanism of Darunavir (DRV)'s ...... V-1 To Develop DRV Resistance.

@en

Mechanism of Darunavir (DRV)'s ...... V-1 To Develop DRV Resistance.

@nl

type

Item

label

Mechanism of Darunavir (DRV)'s ...... V-1 To Develop DRV Resistance.

@en

Mechanism of Darunavir (DRV)'s ...... V-1 To Develop DRV Resistance.

@nl

prefLabel

Mechanism of Darunavir (DRV)'s ...... V-1 To Develop DRV Resistance.

@en

Mechanism of Darunavir (DRV)'s ...... V-1 To Develop DRV Resistance.

@nl

P1476

Mechanism of Darunavir (DRV)'s ...... IV-1 To Develop DRV Resistance

@en

P2093

Arun K Ghosh

http://www.w3.org/2001/XMLSchema#string

Debananda Das

http://www.w3.org/2001/XMLSchema#string

Hiroaki Mitsuya

http://www.w3.org/2001/XMLSchema#string

Hiromi Aoki-Ogata

http://www.w3.org/2001/XMLSchema#string

Hironori Hayashi

http://www.w3.org/2001/XMLSchema#string

Manabu Aoki

http://www.w3.org/2001/XMLSchema#string

P2860

TMC310911, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, Shows In Vitro an Improved Resistance Profile and Higher Genetic Barrier to Resistance Compared with Current Protease Inhibitors

P2' Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran Moiety

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir

Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada

Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care

Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors

Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay

Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.

HIV-1 antiretroviral resistance: scientific principles and clinical applications

In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.

P31

scholarly article

P356

10.1128/MBIO.02425-17

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yuki Takamatsu

P577

2018-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29511083

http://www.w3.org/2001/XMLSchema#string

P932

5844992

http://www.w3.org/2001/XMLSchema#string